HIGHFDA DRUG

Carvedilol Tablets 12.5 mg Recall Expanded for NNCI Impurity Above FDA Limit (2025)

The FDA recalls 26,628 cartons of Carvedilol Tablets USP 12.5 mg distributed nationwide. The product fails CGMP standards due to NNCI impurity exceeding FDA limits. Stop using and contact The Harvard Drug Group LLC and Rugby Laboratories for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
August 20, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
August 20, 2025
Hazard Level
HIGH
Brands
Major Pharmaceuticals, CARVEDILOL
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Major Pharmaceuticals, CARVEDILOL
Product type
Carvedilol Tablets 12.5 mg
Model numbers
Lot #: T05693, Exp. Date 03/2026
UPC codes
0904-7305, 0904-7306, 0904-7307, 0904-7308, 0904-7305-61, 0904-7306-61, 0904-7307-61, 0904-7308-61
Sizes
100-tablet carton
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    August 20, 2025

  2. Reported by FDA DRUG

    August 27, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories or your healthcare provider for guidance. Notification method: Letter

About This Product

Carvedilol is a beta-blocker used to treat high blood pressure and heart failure. Manufacturers distribute in tablet form to patients nationwide.

Why This Is Dangerous

NNCI impurity above FDA limits could pose health risks; exact clinical implications depend on exposure and patient factors.

Industry Context

This recall is not described as part of a broader pattern in the provided data.

Real-World Impact

The recall requires patients and healthcare providers to review exposure, discontinue use where advised, and coordinate replacements or alternatives.

Practical Guidance

How to identify if yours is affected

  1. Check package for NDC 0904-7307-61
  2. Look for Lot T05693 and Exp. 03/2026
  3. Verify packaging indicates Major Pharmaceuticals and Rugby Laboratories

Where to find product info

FDA recall page linked in enforcement report; manufacturer letters to healthcare providers

What timeline to expect

Processing and guidance to be provided via recall letters; replacements or refunds depend on provider and distributor timelines

If the manufacturer is unresponsive

  • Escalate to FDA MedWatch
  • Contact state pharmacy board
  • Seek guidance from healthcare provider on alternatives

How to prevent similar issues

  • Verify NDC numbers before dispensing prescriptions
  • Monitor for NNCI-related recalls in drug databases
  • Keep patients informed about recall notices

Documentation advice

Keep recall letters, patient exposure records, and communications with pharmacy or provider as documentation

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Carvedilol Tablets USP, 12.5 mg, 100-tablet carton. Packaged and distributed by Major Pharmaceuticals, Indianapolis, IN 46268, USA. NDC 0904-7307-61. Lot: T05693. Expiration: 03/2026. Quantity: 26,628 cartons. Distribution: Nationwide in the United States.

Reported Incidents

No specific patient incidents or injuries are detailed in the recall notice. Hazard is chemical impurity risk; no incident counts provided.

Key Facts

  • NNCI impurity above 4.0 ppm

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANT
Injury Types
POISONINGOTHER

Product Details

Model Numbers
Lot #: T05693
Exp. Date 03/2026
UPC Codes
0904-7305
0904-7306
0904-7307
+5 more
Affected States
ALL
Report Date
August 27, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls